Our Story

Noven – 1987 to Today

Noven's history began in 1987 in Miami, Florida, with the mission to develop differentiated prescription transdermal drug delivery systems (patches) to benefit patients across a range of therapeutic conditions. Today, Noven is the US platform for Hisamitsu, the world's largest patch manufacturer, with fully integrated R&D, clinical, manufacturing, and sales functions offering prescription products in the areas of women's health and mental health.

History

February-1998
Formation of Novogyne joint venture in Women's Health
February-1996
Launch of Vivelle® (estradiol transdermal system), the first adhesive matrix estrogen patch
February-1988
Noven becomes a public company
February-1987
Noven founded by Steven Sablotsky

Fast Facts

Core Business:
Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.

Year of Incorporation:
1987

Employees:
Over 300

Board Member & Chief Executive Officer:
Takeshi Masumoto

Media, General Business
& Other Inquiries:
CorporateAffairs@noven.com

Partnering and Other Business Development Opportunities
Tel: 551-233-2700
BusDev@noven.com

Employment Inquiries:
Marilyn Reynaldo
Associate Director –
Talent Acquisition
mreynaldo@noven.com

Community Support:
Corporate Social Responsibility

Affiliated Companies:
Noven is a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. – bringing the benefits of patch therapy to patients around the world.

Noven's commercialized products are marketed and sold through Noven Therapeutics, LLC.

Grove Pharmaceuticals is the generic division of Noven Therapeutics, LLC.